Episode 307
Angela is joined by Dr. Dale Bredesen, who discusses the prevalence of Alzheimer's disease and the difference between Alzheimer's and other forms of dementia.
He emphasises the importance of early detection and treatment, as Alzheimer's is a progressive disease that can be present for many years before symptoms appear. Dr. Bredesen explains the four phases of Alzheimer's and the potential for prevention and reversal of cognitive decline through lifestyle interventions.
KEY TAKEAWAYS
BEST MOMENTS
"Your generation is the first generation that does not have to fear Alzheimer's."
"We can pretty much prevent it or do early reversals in just about everyone."
"We do see people even in late stages where we get some improvement, but they don't tend to come all the way back to normal."
"Sleep is one of the ways that you stay sharp, that you improve your processing speed."
VALUABLE RESOURCES
Get a free snapshot of your health and personalised report at www.yourtotalhealthcheck.com
Join The High Performance Health Community
Free Fasting Guide - www.angelafosterperformance.com/fasting
Podcast Shownotes - www.angelafosterperformance.com/podcasts
Episode 212 - https://omny.fm/shows/high-performance-health/the-science-of-manifestation-how-to-use-neuroplast
ABOUT THE GUEST
Dale Bredesen, MD, received his undergraduate degree from Caltech and his medical degree from Duke University. He served as resident and chief resident in neurology at the University of California, San Francisco (UCSF) and as postdoctoral fellow in the laboratory of Nobel Laureate Professor Stanley Prusiner. He was a faculty member at UCLA from 1989 to 1994 and was then recruited by the Burnham Institute to direct the Program on Aging. In 1998, he became the founding president and CEO of the Buck Institute for Research on Aging and adjunct professor at UCSF. In 2013, he returned to the University of California, Los Angeles (UCLA) as director of the Easton Center for Alzheimer’s Disease Research and he is currently a professor.
The Bredesen Laboratory studies basic mechanisms underlying the neurodegenerative process and the translation of this knowledge into effective therapeutics for Alzheimer’s disease and other neurodegenerative conditions, which has led to the publication of over 200 research papers. He is the principal investigator for the Alzheimer’s Disease Research Center at UCLA. He established the ADDN (Alzheimer’s Drug Development Network) with Dr. Varghese John in 2008, leading to the identification of new classes of therapeutics for Alzheimer’s disease. His group has developed a new approach to the treatment of Alzheimer’s disease, the MEND protocol, and this approach has le
Published on 1 year, 11 months ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate